Here are the S-1 registration statements from Wellgistics Health, Inc. (WGRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow WGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGRX filings page.
DataMeds AI, Inc. is registering 34,462,058 shares of common stock for resale by existing selling stockholders. The shares consist of previously issued stock, shares issuable from May 2026 convertible notes and related Series A preferred stock, and shares underlying PIPE and placement agent warrants. The company itself is not selling stock and will receive no proceeds from these resales, only potential cash from any future PIPE or placement agent warrant exercises.
These financings use variable conversion prices, floors as low as $1.00 per share, and Series A preferred stock with a 10% annual dividend added to stated value, which can substantially increase shares issued over time. With 2,847,198 shares outstanding as of July 27, 2026, the company estimates up to 36,027,113 shares could be outstanding if all May 2026 notes convert at $1.00 and all PIPE and placement agent warrants are exercised, implying significant dilution. DataMeds operates a micro health ecosystem combining wholesale distribution, a technology hub platform and a multi‑state pharmacy. It recently completed a 1‑for‑50 reverse split to regain Nasdaq’s $1.00 bid requirement and is working to restore compliance with Nasdaq’s $2.5 million stockholders’ equity standard by October 12, 2026.